HeimBSX • NYSE
add
Boston Scientific Corporation
90,21 $
Fyrir opnun:(0,86%)+0,78
90,99 $
Lokað: 27. nóv., 00:09:45 GMT-5 · USD · NYSE · Lagalegir fyrirvarar
Við síðustu lokun
89,25 $
Dagbil
89,10 $ - 90,39 $
Árabil
53,93 $ - 91,93 $
Markaðsvirði
134,07 ma. USD
Meðalmagn
6,92 m.
V/H-hlutf.
74,57
A/V-hlutfall
-
Aðalkauphöll
NYSE
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Tekjur | 4,21 ma. | 19,34% |
Rekstrarkostnaður | 2,17 ma. | 20,38% |
Nettótekjur | 469,00 m. | -7,13% |
Hagnaðarhlutfall | 11,14 | -22,21% |
Hagnaður á hvern hlut | 0,63 | 26,00% |
EBITDA | 1,02 ma. | 12,65% |
Virkt skatthlutfall | 29,90% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 2,50 ma. | 162,82% |
Heildareignir | 38,08 ma. | 11,85% |
Heildarskuldir | 17,12 ma. | 14,80% |
Eigið fé alls | 20,96 ma. | — |
Útistandandi hlutabréf | 1,47 ma. | — |
Eiginfjárgengi | 6,35 | — |
Arðsemi eigna | 4,77% | — |
Ávöxtun eigin fjár | 5,63% | — |
Peningaflæði
Breyting á handbæru fé
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | 469,00 m. | -7,13% |
Handbært fé frá rekstri | 1,00 ma. | 43,55% |
Reiðufé frá fjárfestingum | -1,43 ma. | -624,37% |
Reiðufé frá fjármögnun | 7,00 m. | -56,25% |
Breyting á handbæru fé | -412,00 m. | -180,31% |
Frjálst peningaflæði | 612,38 m. | 43,29% |
Um
Boston Scientific Corporation, headquartered in Marlborough, Massachusetts and incorporated in Delaware, is a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. Boston Scientific is widely known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. With the full acquisition of Cameron Health in June 2012, the company also became notable for offering a minimally invasive implantable cardioverter-defibrillator which they call the EMBLEM subcutaneous implantable defibrillator. Wikipedia
Framkvæmdastjóri
Stofnsett
29. jún. 1979
Höfuðstöðvar
Vefsvæði
Starfsfólk
48.000